Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: Thalidomide + TAS-102 in mCRC
NCT05266820Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of thalidomide in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 100 months. Status: unknown.
02
Drugs
thalidomide
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05266820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266820.